MELBOURNE Australia 07 June 2018: Imugene Limited (ASX:IMU) (Imugene), a clinical stage immuno-oncology company, today announced it has received commitments for a placement to institutional and sophisticated investors in Australia and internationally to raise approximately A$12 million (Placement). The offer price for the Placement was A$0.027 per new share (with 1 new option for every 3 new shares issued with an exercise price of A$0.040 per new option exercisable on or before 30 November 2021. The entire Placement is subject to shareholder approval at a general meeting expected to be held on or around 9 July 2018.
For further information please download PDF attached:
Download this document